{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:39:25Z","timestamp":1790563165279,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bioactmat.2022.09.012","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T19:17:49Z","timestamp":1663701469000},"page":"531-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Honglan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-904X","authenticated-orcid":false,"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-1288","authenticated-orcid":false,"given":"Zhiqing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioactmat.2022.09.012_bib1","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bioactmat.2022.09.012_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"12","key":"10.1016\/j.bioactmat.2022.09.012_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/bloodadvances.2017005561","article-title":"Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy","volume":"1","author":"Vick","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bioactmat.2022.09.012_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bioactmat.2022.09.012_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.05.022","article-title":"Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis","volume":"85","author":"Yang","year":"2016","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.bioactmat.2022.09.012_bib6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00277-021-04551-7","article-title":"Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis","volume":"100","author":"Lu","year":"2021","journal-title":"Ann. Hematol."},{"issue":"17","key":"10.1016\/j.bioactmat.2022.09.012_bib7","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bioactmat.2022.09.012_bib8","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bioactmat.2022.09.012_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101169","article-title":"Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play","volume":"14","author":"Zhang","year":"2021","journal-title":"Transl Oncol"},{"issue":"21","key":"10.1016\/j.bioactmat.2022.09.012_bib10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bioactmat.2022.09.012_bib11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bioactmat.2022.09.012_bib12","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.bioactmat.2022.09.012_bib13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.seminhematol.2018.07.006","article-title":"Low dose ruxolitinib plus HLH-94 protocol: a potential choice for secondary HLH","volume":"57","author":"Wang","year":"2020","journal-title":"Semin. Hematol."},{"issue":"12","key":"10.1016\/j.bioactmat.2022.09.012_bib15","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bioactmat.2022.09.012_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12185-020-02936-4","article-title":"Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children","volume":"112","author":"Wei","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.bioactmat.2022.09.012_bib17","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bioactmat.2022.09.012_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.bioactmat.2022.09.012_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.apsb.2017.12.002","article-title":"Biomimetic nanoparticles for inflammation targeting","volume":"8","author":"Jin","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acs.nanolett.8b03439","article-title":"Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles","volume":"19","author":"Li","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.bioactmat.2022.09.012_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2020.02.043","article-title":"Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer","volume":"321","author":"Liu","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2022.09.012_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120159","article-title":"Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity","volume":"255","author":"Hu","year":"2020","journal-title":"Biomaterials"},{"issue":"27","key":"10.1016\/j.bioactmat.2022.09.012_bib24","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bioactmat.2022.09.012_bib25","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1021\/acsnano.8b08964","article-title":"Erythroliposomes: integrated hybrid nanovesicles composed of erythrocyte membranes and artificial lipid membranes for pore-forming toxin clearance","volume":"13","author":"He","year":"2019","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.bioactmat.2022.09.012_bib26","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/acsnano.5b02132","article-title":"Detoxification of organophosphate poisoning using nanoparticle bioscavengers","volume":"9","author":"Pang","year":"2015","journal-title":"ACS Nano"},{"issue":"37","key":"10.1016\/j.bioactmat.2022.09.012_bib27","doi-asserted-by":"crossref","first-page":"13481","DOI":"10.1073\/pnas.1412420111","article-title":"Clearance of pathological antibodies using biomimetic nanoparticles","volume":"111","author":"Copp","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bioactmat.2022.09.012_bib28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41565-018-0254-4","article-title":"Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis","volume":"13","author":"Zhang","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"43","key":"10.1016\/j.bioactmat.2022.09.012_bib29","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1073\/pnas.1714267114","article-title":"Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management","volume":"114","author":"Thamphiwatana","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2022.09.012_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.addr.2021.03.021","article-title":"Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies","volume":"173","author":"Liu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.bioactmat.2022.09.012_bib31","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.bioactmat.2022.09.012_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002855","article-title":"Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report","volume":"9","author":"Sackstein","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"25","key":"10.1016\/j.bioactmat.2022.09.012_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf7820","article-title":"Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs","volume":"7","author":"Park","year":"2021","journal-title":"Sci. Adv."},{"issue":"30","key":"10.1016\/j.bioactmat.2022.09.012_bib34","doi-asserted-by":"crossref","first-page":"e2001808","DOI":"10.1002\/adma.202001808","article-title":"Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity","volume":"32","author":"Jiang","year":"2020","journal-title":"Adv Mater"},{"issue":"2","key":"10.1016\/j.bioactmat.2022.09.012_bib35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1006\/jmbi.1997.0933","article-title":"Solution structure of recombinant human interleukin-6","volume":"268","author":"Xu","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"47","key":"10.1016\/j.bioactmat.2022.09.012_bib36","doi-asserted-by":"crossref","first-page":"40043","DOI":"10.1074\/jbc.M112.405597","article-title":"Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention","volume":"287","author":"Veverka","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.bioactmat.2022.09.012_bib37","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1073\/pnas.80.19.5842","article-title":"Cloning and expression of murine immune interferon cDNA","volume":"80","author":"Gray","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.matt.2020.05.017","article-title":"Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles","volume":"3","author":"Ma","year":"2020","journal-title":"Matter"},{"issue":"7","key":"10.1016\/j.bioactmat.2022.09.012_bib39","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.7150\/thno.42385","article-title":"Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bioactmat.2022.09.012_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fimmu.2017.00061","article-title":"Metabolism supports macrophage activation","volume":"8","author":"Langston","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2022.09.012_bib41","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","article-title":"The metabolic signature of macrophage responses","volume":"10","author":"Viola","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bioactmat.2022.09.012_bib42","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3324\/haematol.2020.253781","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bioactmat.2022.09.012_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bioactmat.2022.09.012_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bioactmat.2022.09.012_bib45","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bioactmat.2022.09.012_bib46","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3324\/haematol.2018.209551","article-title":"Senescence-accelerated mice (SAMP1\/TA-1) treated repeatedly with lipopolysaccharide develop a condition that resembles hemophagocytic lymphohistiocytosis","volume":"104","author":"Tsuboi","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bioactmat.2022.09.012_bib47","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.1820704116","article-title":"Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice","volume":"116","author":"Wang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bioactmat.2022.09.012_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cytogfr.2014.10.001","article-title":"Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders","volume":"26","author":"Brisse","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bioactmat.2022.09.012_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","article-title":"Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis","volume":"16","author":"Hu","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"14","key":"10.1016\/j.bioactmat.2022.09.012_bib51","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1021\/acsami.6b00036","article-title":"Enhanced antitumor activity of EGFP-EGF1-conjugated nanoparticles by a multitargeting strategy","volume":"8","author":"Zhang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"10","key":"10.1016\/j.bioactmat.2022.09.012_bib52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/1061186X.2018.1452243","article-title":"Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer","volume":"26","author":"Zhang","year":"2018","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1021\/acs.nanolett.9b03753","article-title":"Pseudoneutrophil cytokine sponges disrupt myeloid expansion and tumor trafficking to improve cancer immunotherapy","volume":"20","author":"Li","year":"2020","journal-title":"Nano Lett."},{"issue":"10","key":"10.1016\/j.bioactmat.2022.09.012_bib54","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.apsb.2020.07.019","article-title":"Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bioactmat.2022.09.012_bib55","article-title":"Bispecific antibody inhalation therapy for redirecting stem cells from the lungs to repair heart injury","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioactmat.2022.09.012_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.trsl.2016.07.023","article-title":"Use of a mouse model to identify a blood biomarker for IFN\u03b3 activity in pediatric secondary hemophagocytic lymphohistiocytosis","volume":"180","author":"Buatois","year":"2017","journal-title":"Transl. Res."},{"issue":"2","key":"10.1016\/j.bioactmat.2022.09.012_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.immuni.2020.12.001","article-title":"The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells","volume":"54","author":"Yousif","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bioactmat.2022.09.012_bib58","article-title":"Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome","volume":"2","author":"Chen","year":"2021","journal-title":"Cell Rep Med"},{"issue":"9927","key":"10.1016\/j.bioactmat.2022.09.012_bib59","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bioactmat.2022.09.012_bib60","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03006-2020","article-title":"Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome","volume":"56","author":"Chen","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.bioactmat.2022.09.012_bib61","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.bioactmat.2022.09.012_bib62","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaci.2020.09.016","article-title":"Highways to hell: mechanism-based management of cytokine storm syndromes","volume":"146","author":"Canna","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioactmat.2022.09.012_bib63","article-title":"Radiotherapy and cytokine storm: risk and mechanism","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bioactmat.2022.09.012_bib64","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bioactmat.2022.09.012_bib65","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/art.24448","article-title":"Induction of CCR2-dependent macrophage accumulation by oxidized phospholipids in the air-pouch model of inflammation","volume":"60","author":"Kadl","year":"2009","journal-title":"Arthritis Rheum."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X22003966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X22003966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:33:53Z","timestamp":1762785233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X22003966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":65,"alternative-id":["S2452199X22003966"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2022.09.012","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2022.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}